Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 11/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.72 |
| ▸ | CDK2 | P24941 | 4/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5193689 | 0.90 | FLT3 (1.00) | FLT3PDGFRACDK2SRCCCNE1 | |
| SCHEMBL5193682 | 0.90 | FLT3 (1.00) | FLT3PDGFRACDK2SRCCCNE1 | |
| Hydrochloric Acid SCHEMBL5195535 | 0.89 | FLT3 (0.98) | FLT3PDGFRACDK2SRCCCNE1 | |
| Hydrochloric Acid SCHEMBL5195542 | 0.89 | FLT3 (0.98) | FLT3PDGFRACDK2SRCCCNE1 | |
| SCHEMBL21880695 | 0.84 | FLT3 (1.00) | FLT3PDGFRACDK2SRCCCNE1 | |
| SCHEMBL24336620 | 0.84 | FLT3 (1.00) | FLT3PDGFRACDK2SRCCCNE1 | |
| SCHEMBL21880693 | 0.84 | FLT3 (1.00) | FLT3PDGFRACDK2SRCCCNE1 | |
| SCHEMBL21802047 | 0.83 | FLT3 (1.00) | FLT3PDGFRA | |
| SCHEMBL21802045 | 0.83 | FLT3 (0.81) | FLT3PDGFRA | |
| SCHEMBL5193129 | 0.82 | FLT3 (0.85) | FLT3PDGFRACDK2SRCCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028087-B2 | 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2021-06-08 | — | — | US | disclosed |
| US-20200087306-A1 | 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087306-A1 | 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | FLT3, CDK9, CDK6 | FLT3 1/4885PDGFRA 9/4885CDK2 4/4885 |
| US-11028087-B2 | 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions | FLT3, CDK9, CDK6 | FLT3 1/4885PDGFRA 9/4885CDK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.